Last reviewed · How we verify
Consolidation, III HiDAraC cycle
HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells.
HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML) consolidation therapy.
At a glance
| Generic name | Consolidation, III HiDAraC cycle |
|---|---|
| Also known as | - Cytosine arabinoside [Ara-C], - 2-CdA [Cladribine, 2-Chlorodeoxyadenosine] |
| Sponsor | dr hab. n. med. Agnieszka Wierzbowska |
| Drug class | Nucleoside analog / Antimetabolite chemotherapy |
| Target | DNA/RNA synthesis (cytidine deaminase inhibition pathway) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cytarabine is a nucleoside analog that incorporates into DNA and RNA, disrupting synthesis and leading to cell death. The high-dose consolidation approach is used post-induction in acute myeloid leukemia (AML) to eliminate residual disease and improve long-term remission rates. This Phase 3 trial likely evaluates efficacy and safety of this consolidation strategy in AML patients.
Approved indications
- Acute myeloid leukemia (AML) consolidation therapy
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Mucositis
- Nausea and vomiting
- Cerebellar syndrome (high-dose cytarabine toxicity)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: